The benchmarking portal gives you access to all reports available for STD, LTD, FML & WC.
Infographic: GLP-1 Medications
GLP-1 medications are now among the largest single-class line items on the employer pharmacy ledger, and benefits leaders are being asked to make consequential coverage decisions before the evidence they need fully exists. IBI's new systematic review synthesizes peer-reviewed clinical trials, employer claims studies, health economics analyses, and benefits industry surveys to give members an honest account of what the research shows, where it falls short, and what it means for coverage and program design.
Key findings:
- The workforce burden of obesity costs US employers an estimated $347.5 billion annually across medical, disability, and productivity categories, concentrated in the conditions GLP-1s have the strongest clinical evidence to address.
- Major trials demonstrate a 20 percent reduction in cardiovascular events, up to 63 percent reduction in sleep apnea severity, and clinically meaningful reductions in knee osteoarthritis pain, outcomes directly relevant to disability cost and return-to-work timelines.
- Fewer than one-third of commercially insured GLP-1 users without diabetes remain on therapy after one year, and patients who stop regain approximately two-thirds of their prior weight loss within 12 months.
- Drug spend is outpacing documented medical cost offsets. Most employers covering GLP-1s are seeing premium and pharmacy cost increases without offsetting reductions in medical claims at the projected scale.